LivaNova PLC (the " Company " or " LivaNova ") announces on 11 August 2016, that Jacques Gutedel, who is a PDMR of LivaNova, on 9 August 2016 disposed of 4,000 ordinary shares of £1.00 each in the capital of the Company (the " Ordinary Shares ") for an average price of US $60.524 per Ordinary Share. As a result of this transaction, Jacques Gutedel currently holds 10,948 Ordinary Shares, representing 0.02 per cent of the Company's issued share capital.
This announcement is made pursuant to the Disclosure and Transparency Rule 3.1.4R.
Further details and a copy of the applicable Form 4, "Statement of Changes in Beneficial Ownership of Securities," to be filed with the U.S. Securities & Exchange Commission, can be found at the SEC website, www.sec.gov , and the LivaNova PLC web site, www.livanova.com
LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and listed on the Official List of the UK's Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol "LIVN".
For more information, please visit www.livanova.com , or contact:
Investor Relations and Media
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332